NASDAQ:PBM Psyence Biomedical Q2 2025 Earnings Report $3.28 +0.13 (+4.13%) As of 09:50 AM Eastern ProfileEarnings HistoryForecast Psyence Biomedical EPS ResultsActual EPS$25.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APsyence Biomedical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APsyence Biomedical Announcement DetailsQuarterQ2 2025Date1/23/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Psyence Biomedical Earnings HeadlinesPsyence Biomedical (NASDAQ:PBM) Stock Price Down 5.7% - Here's What HappenedAugust 1, 2026 | americanbankingnews.comPsyence BioMed to Engage U.S. Stakeholders on Psychedelic Medicine Research and Ibogaine Supply InitiativesMay 15, 2026 | quiverquant.comQLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.August 5 at 1:00 AM | InvestorPlace (Ad)Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and ManufacturingMay 15, 2026 | globenewswire.comPsyence Biomedical Ltd. Begins Phase IIb Clinical Trial for NPX-5 Psilocybin Treatment in Cancer PatientsApril 23, 2026 | quiverquant.comQPsyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment DisorderApril 23, 2026 | financialpost.comFSee More Psyence Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Psyence Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Psyence Biomedical and other key companies, straight to your email. Email Address About Psyence BiomedicalPsyence Biomedical (NASDAQ:PBM) engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.View Psyence Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Caterpillar’s Record Quarter May Have Reset the Stock’s CeilingGrab Holdings Stock Forms Bottom After Strong Beat-and-Raise QuarterThe AI Chip Stock Making a Quiet Move Toward DominanceThe Real Reason Amazon Hit a $3 Trillion ValuationApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-Caps Upcoming Earnings Airbnb (8/6/2026)Warner Bros. Discovery (8/6/2026)Monster Beverage (8/6/2026)Canadian Natural Resources (8/6/2026)ConocoPhillips (8/6/2026)Cheniere Energy (8/6/2026)Petroleo Brasileiro S.A.- Petrobras (8/6/2026)Targa Resources (8/6/2026)Aflac (8/6/2026)Howmet Aerospace (8/6/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
